



P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
P. (070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches
Patentamt

Generaldirektion 1

European
Patent Office

Directorate General 1

Office européen
des brevets

Direction générale 1



JANSSEN PHARMACEUTICA N.V.
Turnhoutseweg 30
2340 Beerse
BELGIQUE

EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date

13.09.06

Reference PRD2124-PCT-EPO	Application No./Patent No. 04819600.0 - 2101 PCT/EP2004013162
Applicant/Proprietor JANSSEN PHARMACEUTICA N.V.	

Notification of European publication number and information on the application of Article 67(3) EPC

The provisional protection under Article 67(1) and (2) EPC in the individual contracting states becomes effective only when the conditions referred to in Article 67(3) EPC have been fulfilled (for further details, see information brochure of the European Patent Office "National Law relating to the EPC" and additional information in the Official Journal of the European Patent Office).

A request has been made for extension of the patent to: AL HR LT LV MK YU
See Official Journal 1-2/1994 for further information on provisional protection.

Pursuant to Article 158(1) EPC the publication under Article 21 PCT of an international application for which the European Patent Office is a designated Office takes the place of the publication of a European patent application.

The bibliographic data of the above-mentioned Euro-PCT application will be published on 11.10.06 in Section I.1 of the European Patent Bulletin. The European publication number is 1709011.

In all future communications to the European Patent Office, please quote the application number plus Directorate number.

Receiving Section





P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
P. (070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches
Patentamt

Generaldirektion 1

European
Patent Office

Directorate General 1

Office européen
des brevets

Direction générale 1



JANSSEN PHARMACEUTICA N.V.
Turnhoutsebaan 30
2340 Beerse
BELGIQUE

EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date
07-08-2006

Reference PRD2124-PCT-EPO	Application No./Patent No. 04819600.0 - 2101 PCT/EP2004013162
Applicant/Proprietor JANSSEN PHARMACEUTICA N.V.	

Communication pursuant to Rules 109 and 110 EPC

(1) Amendment of application documents, especially the claims (R. 109 EPC)

The above mentioned international (Euro-PCT) application has entered the European phase, or can do so, once the necessary conditions are fulfilled.

Under Articles 28, 41 PCT, Rules 52, 78 PCT and Rule 86(2) to (4) EPC, the applicant may amend the application documents after receiving the international search report.

Whether or not he has already done so, he now has a further opportunity to file amended claims or other application documents within a non-extendable time limit of one month after notification of the present communication (R. 109 EPC).

The claims applicable on expiry of the above time limit, i.e. those filed on entry into the European phase or in response to the present communication, will form the basis for the calculation of any claims fee to be paid (see page 2) and for any supplementary search to be carried out under Article 157(2) EPC (R. 109 EPC).

**(2) Claims fees under Rule 110 EPC**

If the application documents on which the European grant procedure is to be based comprise more than ten claims, a claims fee shall be payable for the eleventh and each subsequent claim within the period provided for in Rule 107(1) EPC.

- Based on the application documents currently on file, all necessary claims fees have already been paid (or the documents do not comprise more than 10 claims).
- All necessary fees will be/have been debited automatically according to the automatic debit order.
- The claims fees due for the claims to were not paid within the above-mentioned period.

Any non-paid claims fee, either based on the current set of claims or on any amended claims to be filed pursuant to Rule 109 EPC (see page 1), may still be validly paid within a non-extendable period of grace of one month after notification of this communication.

If a payment is made for only some of the claims, it must be indicated for which claims it is intended. If a claims fee is not paid in due time, the claim concerned is deemed to be abandoned (R. 110(4) EPC).

If claims fees have already been paid, but on expiry of the above-mentioned time limit there is a new set of claims containing fewer fee-incurring claims than previously, the claims fees in excess of those due under Rule 110(2), 2nd sentence, EPC will be refunded (R. 110(3) EPC).

You are reminded that any supplementary search under Article 157(2) EPC will relate only to the last set of claims applicable on expiry of the above time limit AND will be confined to those fee-incurring claims for which fees have been paid in due time.

The fee for the eleventh and each subsequent claim is EUR 45,00.

Receiving Section



P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
T (070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches
Patentamt

Generaldirektion 1

European
Patent Office

Directorate General 1

Office européen
des brevets

Direction générale 1

JANSSEN PHARMACEUTICA N.V.
Turnhoutseweg 30
2340 Beerse
BELGIQUE



EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date
02.08.06

Reference PRD2124-PCT-EPO	Application No./Patent No. 04819600.0-2101-EP2004013162
Applicant/Proprietor JANSSEN PHARMACEUTICA N.V.	

Refund of fees

The following fees were paid in respect of the application 04819600.0:

Fee	Code	Voucher No	Date	Currency	Amount
Examination fee	006	00425912	20.06.06	EUR	1 490,00

REFUND ORDER

1. In accordance with Art. 12(1) Rules relating to Fees in conjunction with Rule 6(3) EPC, 20 % of the examination fee will be refunded.
2. The refund will be done by:
CREDITING THE DEPOSIT ACCOUNT 28020034.

Amount refundable:	Code	Currency	Amount	Voucher No
	006	EUR	298,00	00491900
Total:		EUR	298,00	

The Authorising Officer
Lodolo
(49)(89)23992039

